Eloise Williams

Eloise Williams

Auto-generated profile, based on publicly available information

Eloise Williams

Department of Infectious Diseases, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity , Melbourne, Victoria

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2020 in Journal of Clinical Microbiology
Verified
Journal Article
Open access
PDF file
EWEloise Williams
Eloise Williams
KBKatherine Bond
Katherine Bond
BZBowen Zhang
Bowen Zhang
MPMark Putland
Mark Putland
DWDeborah A Williamson
Deborah A Williamson
Diagnostic testing for COVID-19 is central to controlling the global pandemic. …

14 March 2024 in Clinical Microbiology Reviews
Verified
Journal Article
Closed access
EWEloise Williams
Eloise Williams
KSKate Seib
Kate Seib
CFChristopher K. Fairley
Christopher K. Fairley
GPGeorgina L. Pollock
Georgina L. Pollock
JHJane S. Hocking
Jane S. Hocking
DWDeborah A. Williamson
Deborah A. Williamson
SUMMARY: Neisseria gonorrhoeae infection is an important public health issue, with an annual global incidence of 87 million. N. gonorrhoeae infection causes significant morbidity and can have serious long-term impacts on reproductive and neonatal health and may rarely cause life-threatening disease. Global rates of N. gonorrhoeae infection have increased over the past 20 years. Importantly, rates of antimicrobial resistance to key antimicrobials also continue to increase, with the United States Centers for Disease Control and Prevention identifying drug-resistant N. gonorrhoeae as an urgent threat to public health. This review summarizes the current evidence for N. gonorrhoeae vaccines, including historical clinical trials, key N. gonorrhoeae vaccine preclinical studies, and studies of the impact of Neisseria meningitidis vaccines on N. gonorrhoeae infection. A comprehensive survey of potential vaccine antigens, including those identified through traditional vaccine immunogenicity approaches, as well as those identified using more contemporary reverse vaccinology approaches, are also described. Finally, the potential epidemiological impacts of a N. gonorrhoeae vaccine and research priorities for further vaccine development are described.

27 July 2023 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
EWEloise Williams
Eloise Williams
DWDeborah A Williamson
Deborah A Williamson
JHJane S Hocking
Jane S Hocking

1 February 2021 in Journal of Medical Microbiology
Verified
Journal Article
Open access
EWEloise Williams
Eloise Williams
NINicole Isles
Nicole Isles
BCBrian Chong
Brian Chong
KBKatherine Bond
Katherine Bond
YYYano Yoga
Yano Yoga
DWDeborah A. Williamson
Deborah A. Williamson
Saliva has recently been proposed as a suitable specimen for the diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Use of saliva as a diagnostic specimen may present opportunities for SARS-CoV-2 reverse transcription polymerase chain reaction (RT-PCR) testing in remote and low-resource settings. Determining the stability of SARS-CoV-2 RNA in saliva over time is an important step in determining optimal storage and transport times. We undertook an in vitro study to assess whether SARS-CoV-2 could be detected in contrived saliva samples. The contrived saliva samples comprised 10 ml pooled saliva spiked with gamma-irradiated SARS-CoV-2 to achieve a concentration of 2.58×104 copies ml SARS-CoV-2, which was subsequently divided into 2 ml aliquots comprising: (i) neat saliva; and a 1 : 1 dilution with (ii) normal saline; (iii) viral transport media, and (iv) liquid Amies medium. Contrived samples were made in quadruplicate, with two samples of each stored at either: (i) room temperature or (ii) 4 °C. SARS-CoV-2 was detected in all SARS-CoV-2 spiked samples at time point 0, day 1, 3 and 7 at both storage temperatures using the N gene RT-PCR assay and time point 0, day 1 and day 7 using the Xpert Xpress SARS-CoV-2 (Cepheid, Sunnyvale, USA) RT-PCR assay. The ability to detect SARS-CoV-2 in saliva over a 1 week period is an important finding that presents further opportunities for saliva testing as a diagnostic specimen for the diagnosis of SARS-CoV-2.

14 February 2022 in Vaccine
Verified
Journal Article
Closed access
EWEloise Williams
Eloise Williams
KCKathrine Craig
Kathrine Craig
CCChristopher Chiu
Christopher Chiu
HDHugh Davies
Hugh Davies
SEStephanie Ellis
Stephanie Ellis
NYNaho Yamazaki
Naho Yamazaki

23 May 2023 in Pathology
Verified
Journal Article
Open access
EWEloise Williams
Eloise Williams
MMMichael Moso
Michael Moso
CLChuan Kok Lim
Chuan Kok Lim
DCDoris Chibo
Doris Chibo
SNSuellen Nicholson
Suellen Nicholson
DWDeborah Anne Williamson
Deborah Anne Williamson
Over the past decade there have been technical advances in human immunodeficiency virus (HIV) assays and updates to testing regulations that have substantially changed the landscape of laboratory testing for HIV. In addition, there have been significant changes in the epidemiology of HIV in Australia in the context of highly effective contemporary biomedical treatment and prevention strategies. Here, we provide an update on contemporary issues for the laboratory detection and confirmation of HIV in Australia. These include (1) the impact of early treatment and biological prevention strategies on the serological and virological detection of HIV; (2) the updated national HIV laboratory case definition and its interaction with testing regulations, public health and clinical guidelines; and (3) novel strategies for the laboratory detection of HIV, including the incorporation of HIV nucleic acid amplification tests (NAATs) into testing algorithms. These developments present an opportunity to develop a nationally consistent contemporary HIV testing algorithm that would result in optimisation and standardisation of HIV testing in Australia.